Quick Answer
Candel Therapeutics, Inc. reported Research And Development Expense of $30.50 million for the year ending 2025.
- Candel Therapeutics, Inc. showed an increase of +57.9% in Research And Development Expense from 2024 to 2025.
- This data is from Candel Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $1.80 million | Q3 2020: $1.81 million | Q1 2021: $2.75 million | Q2 2021: $3.29 million | Q3 2021: $5.27 million | Q1 2022: $5.42 million | Q2 2022: $5.02 million | Q3 2022: $5.38 million | Q1 2023: $5.47 million | Q2 2023: $5.93 million | Q3 2023: $5.85 million | Q1 2024: $4.10 million | Q2 2024: $4.98 million | Q3 2024: $5.42 million | Q1 2025: $4.02 million | Q2 2025: $6.99 million | Q3 2025: $8.46 million.
- Over the full 6 years of available data (2020 to 2025), Candel Therapeutics, Inc.'s Research And Development Expense has grown by 248.4%.
- Historical annual values: Fiscal year 2025: $30.50 million | Fiscal year 2024: $19.31 million | Fiscal year 2023: $24.51 million | Fiscal year 2022: $20.79 million | Fiscal year 2021: $15.18 million | Fiscal year 2020: $8.75 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: